Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Purchased by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd lifted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIVFree Report) by 35.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,155 shares of the company’s stock after purchasing an additional 4,458 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in Roivant Sciences were worth $193,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Norges Bank acquired a new stake in shares of Roivant Sciences in the 4th quarter worth $41,506,000. Pertento Partners LLP acquired a new stake in Roivant Sciences during the 4th quarter worth about $9,874,000. Vanguard Personalized Indexing Management LLC lifted its position in Roivant Sciences by 26.7% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 18,742 shares of the company’s stock worth $210,000 after acquiring an additional 3,955 shares during the period. First Turn Management LLC acquired a new stake in Roivant Sciences during the 4th quarter worth about $15,312,000. Finally, E Fund Management Co. Ltd. lifted its position in Roivant Sciences by 34.6% during the 4th quarter. E Fund Management Co. Ltd. now owns 48,860 shares of the company’s stock worth $549,000 after acquiring an additional 12,569 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $10.83 on Wednesday. The company has a quick ratio of 27.79, a current ratio of 27.79 and a debt-to-equity ratio of 0.06. Roivant Sciences Ltd. has a twelve month low of $8.24 and a twelve month high of $13.24. The business has a 50-day moving average price of $10.96 and a 200 day moving average price of $10.67. The firm has a market cap of $8.73 billion, a PE ratio of 2.08 and a beta of 1.30.

Wall Street Analyst Weigh In

A number of analysts have commented on ROIV shares. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Monday, April 22nd. Deutsche Bank Aktiengesellschaft lifted their price target on Roivant Sciences from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. TheStreet upgraded Roivant Sciences from a “d” rating to a “c+” rating in a research note on Tuesday, February 13th. The Goldman Sachs Group lifted their price objective on Roivant Sciences from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Finally, Wolfe Research began coverage on Roivant Sciences in a research note on Thursday, February 15th. They set an “outperform” rating and a $17.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, Roivant Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.90.

Check Out Our Latest Report on ROIV

Roivant Sciences Company Profile

(Free Report)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Further Reading

Institutional Ownership by Quarter for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.